Science Explorer Interactive view Map
Company · Nanjing · China

Simcere Pharmaceutical (China)

In research, Simcere Pharmaceutical (China) stands highest in Medicine (#5,876 of 10,443 worldwide), Life Sciences (#4,755 of 7,800 worldwide) and Health Sciences (#7,651 of 11,982 worldwide), 2022–2025. Relative to its size it is most specialised in Oncology, Pulmonary and Respiratory Medicine and Biochemistry, Genetics and Molecular Biology — Oncology is 16.7× its share of world research.

World rank, 2022–2025
#10,634
of 28,054 · #23,410 all time
Rank in China
#1,918
of 3,058
Research works
414
▲ 194% vs 2013–17
Citations
3.3k
8.0 per fractional work
Top-10% rate
13.7%
record average 16.5%
Open access
36%
world 28%

What is Simcere Pharmaceutical (China) known for in research?

The fields where it stands highest, 2022–2025, ranked among every institution above the floor in each field.

FieldWorld rankWhere that sitsTop-10% rateWorksAll time
MedicineField #5,876 of 10,443 12.2%113 #14129
Life SciencesDomain #4,755 of 7,800 14.6%70 #10029
Health SciencesDomain #7,651 of 11,982 12.3%115 #17246

Each strip is that field’s whole ranked pool, with the notch where Simcere Pharmaceutical (China) sits in it, in the colour of the band that rank falls in. The track under the rate is the rate itself: it carries no world mark, because the world rate differs by field (from about 6% to 21% in this record).

Which of those standings moved

The same fields on both windows: where it stood over the whole record, and where it stands in 2022–2025. The distance is the story, and it is the one thing the two rank columns above cannot show.

  1. Medicine#14,129 #5,876
  2. Life Sciences#10,029 #4,755
  3. Health Sciences#17,246 #7,651
all time2022–2025, better2022–2025, worse

A dot further right is a better standing. Fields it was not ranked in over the whole record are left out.

What does Simcere Pharmaceutical (China) specialise in?

Where its research is concentrated relative to its size: Oncology takes 16.7× the share of its output that it takes of world research.

  1. OncologySubfield · 36.1 works17×
  2. Pulmonary and Respiratory MedicineSubfield · 24.2 works8.2×
  3. Biochemistry, Genetics and Molecular BiologyField · 55.9 works5.4×
← less than its size predictsmore →

Location quotient, a volume reading rather than an impact one. It surfaces small, lopsided specialities.

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.09× its world share, 1 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 5.44× its world share, 56 worksBiochemistry, Geneti…Immunology and Microbiology: 5.35× its world share, 10 worksImmunology and Micro…Neuroscience: 0.40× its world share, 1 worksNeurosciencePharmacology, Toxicology and Pharmaceutics: 2.64× its world share, 2 worksPharmacology, Toxico…Chemistry: 0.33× its world share, 1 worksChemistryComputer Science: 0.04× its world share, 1 worksComputer ScienceEngineering: 0.11× its world share, 3 worksEngineeringEnvironmental Science: 0.10× its world share, 1 worksEnvironmental ScienceMaterials Science: 0.27× its world share, 2 worksMaterials SciencePhysics and Astronomy: 0.02× its world share, 0 worksPhysics and AstronomyDentistry: 0.04× its world share, 0 worksDentistryHealth Professions: 0.10× its world share, 0 worksHealth ProfessionsMedicine: 3.05× its world share, 113 worksMedicineNursing: 0.69× its world share, 1 worksNursingVeterinary: 1.59× its world share, 0 worksVeterinaryEconomics, Econometrics and Finance: 0.13× its world share, 1 worksEconomics, Econometr…world share
more than its size predictsabout as predictedless

Rings at 0.5×, and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 5.4×. Every wedge is a field page.

Who are the top researchers at Simcere Pharmaceutical (China)?

Ranked on the composite score, Ran Ding and Wenqing Yang lead among researchers whose main affiliation is Simcere Pharmaceutical (China).

  1. 1 Ran Ding China · #1,357,011 worldwide 11 citations · 19 works
  2. 2 Wenqing Yang China · #1,439,225 worldwide 17 citations · 28 works
All ranked researchers at Simcere Pharmaceutical (China)

Which keywords describe research at Simcere Pharmaceutical (China)?

By fractional works in 2022–2025, weighted toward what it does more of than the world: Targeted Therapy, Chemotherapy, Immunotherapy, Cancer, Tumor Microenvironment, Clinical Trials, Prognostic Factors and Genomic Instability.

▲ more of its work than of the world’s◆ about the world’s share▼ less than the world’s

Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Targeted Therapy23▲ 54×5 topics
  2. Chemotherapy23▲ 17×15 topics
  3. Immunotherapy22▲ 16×17 topics
  4. Cancer21▲ 8.0×33 topics
  5. Tumor Microenvironment20▲ 24×6 topics
  6. Clinical Trials14▲ 11×8 topics
  7. Prognostic Factors13▲ 16×12 topics
  8. Genomic Instability13▲ 60×3 topics
  9. Cancer Genomics10▲ 75×1 topic
  10. Mutational Signatures10▲ 75×1 topic
  11. Immune Checkpoint Blockade10▲ 45×1 topic
  12. PD-1 and PD-L110▲ 45×1 topic
  13. Metastasis9▲ 14×9 topics
  14. Breast Cancer9▲ 20×7 topics
  15. Radiotherapy9▲ 12×8 topics
  16. Gene Expression9▲ 7.3×9 topics
  17. Cancer Therapy8▲ 7.7×14 topics
  18. Biomarkers8▲ 6.0×8 topics
  19. Genomic Profiling8▲ 38×2 topics
  20. Molecular Characterization7▲ 22×6 topics
  21. ALK Inhibitors7▲ 59×1 topic
  22. EGFR Mutations7▲ 59×1 topic
  23. Precision Medicine7▲ 7.9×6 topics
  24. Treatment Guidelines7▲ 17×2 topics
  25. Cell Death7▲ 16×4 topics
  26. Cancer Immunotherapy7▲ 23×3 topics
  27. Clinical Practice Guidelines7▲ 6.2×10 topics
  28. Glycosylation6▲ 30×3 topics
  29. Tumor Regression6▲ 27×2 topics
  30. Ferroptosis6▲ 37×1 topic
  31. Lipid Peroxidation6▲ 27×1 topic
  32. Molecular Classification5▲ 18×4 topics
  33. Cancer Progression5▲ 14×5 topics
  34. Monoclonal Antibodies5▲ 30×3 topics
  35. NK Cell Recognition5▲ 40×1 topic
  36. Natural Killer Cells5▲ 40×1 topic
  37. Tumor Markers5▲ 32×2 topics
  38. Genomic Profiles5▲ 62×1 topic
  39. Lymphoma5▲ 16×3 topics
  40. Small-Cell Lung Cancer5▲ 62×1 topic

Which research topics does Simcere Pharmaceutical (China) publish most on?

By volume in 2022–2025: Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations and Ferroptosis and cancer prognosis.

  1. 1 Cancer Genomics and Diagnostics Cancer Research 10 works
  2. 2 Cancer Immunotherapy and Biomarkers Oncology 10 works
  3. 3 Lung Cancer Treatments and Mutations Pulmonary and Respiratory Medicine 7 works
  4. 4 Ferroptosis and cancer prognosis Pulmonary and Respiratory Medicine 6 works
  5. 5 Immune Cell Function and Interaction Immunology 5 works
  6. 6 Lung Cancer Research Studies Oncology 5 works
  7. 7 Glioma Diagnosis and Treatment Genetics 4 works
  8. 8 CAR-T cell therapy research Oncology 4 works
  9. 9 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 4 works
  10. 10 HER2/EGFR in Cancer Research Oncology 4 works

How open and international is its research?

Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available36.5%not open63.5%

World: 28% of research is openly available.

with international co-authors5.5%domestic only94.5%

World: 19% is written across borders.

How has Simcere Pharmaceutical (China)'s research output changed?

Output in 2018–2022 was 194% higher than in 2013–2017.

201020152020
grewheldshrank

The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.

Other research institutions in Nanjing

All research institutions in Nanjing

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.